Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FBLG 
FibroBiologics, Inc. Common Stock (FBLG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: FBLG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.25
1 Year Target Price $10.25
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.51% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.98M USD | Price to earnings Ratio - | 1Y Target Price 10.25 |
Price to earnings Ratio - | 1Y Target Price 10.25 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 0.53 - 4.41 | Updated Date 08/29/2025 |
52 Weeks Range 0.53 - 4.41 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.36 |
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.12 | Actual -0.12 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -88.11% | Return on Equity (TTM) -559.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 27910645 | Price to Sales(TTM) - |
Enterprise Value 27910645 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 41889100 | Shares Floating 32066138 |
Shares Outstanding 41889100 | Shares Floating 32066138 | ||
Percent Insiders 19.57 | Percent Institutions 12.23 |
Upturn AI SWOT
FibroBiologics, Inc. Common Stock
Company Overview
History and Background
FibroBiologics, Inc. is a biotechnology company focused on the development of fibroblast-based therapeutic solutions for chronic diseases. Founded with the goal of leveraging the unique properties of fibroblasts, the company has focused on research, development, and clinical applications of its core technologies.
Core Business Areas
- Fibroblast-Based Therapies: Development and commercialization of therapies utilizing fibroblasts to treat various diseases.
Leadership and Structure
The company has a management team with experience in biotechnology, drug development, and commercialization. The organizational structure is typical of a biotechnology company, with research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Fibroblast-based therapeutic: FibroBiologics is developing fibroblast-based therapies for chronic diseases. As this is under development, market share data is not yet available. Competitors would include other companies working in cell-based therapies and regenerative medicine.
Market Dynamics
Industry Overview
The regenerative medicine and cell-based therapy market is rapidly growing, driven by increasing demand for novel treatments for chronic diseases. The industry is characterized by intense competition and significant investment in research and development.
Positioning
FibroBiologics aims to be a leader in fibroblast-based therapies, leveraging its proprietary technology and expertise. The company's success depends on successful clinical trials and regulatory approvals.
Total Addressable Market (TAM)
The total addressable market for regenerative medicine is substantial, potentially reaching billions of dollars. FibroBiologics is positioned to capture a portion of this market with successful product development and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary fibroblast technology
- Experienced management team
- Focus on underserved medical needs
Weaknesses
- Limited clinical data
- High development costs
- Dependence on regulatory approvals
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure of clinical trials
Competitors and Market Share
Key Competitors
Competitive Landscape
Without detailed knowledge of FibroBiologics' specific product pipeline and financial information, a precise competitive landscape assessment is not possible. They will compete with companies in the regenerative medicine field.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to funding, research, and development progress. Specific data is unavailable.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates are not readily available.
Recent Initiatives: Recent strategic initiatives may include securing funding, advancing clinical trials, and establishing partnerships.
Summary
FibroBiologics is a biotechnology company in the development stage, focused on fibroblast-based therapies. The company's success hinges on positive clinical trial results and regulatory approvals. As a development stage company, the financial information is dependent on research and development progress and further funding will need to be secured. Key items to watch will be the clinical data and strategic partnerships. The success of their technology will determine their market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website (if available)
- Industry reports
- General market knowledge
Disclaimers:
This analysis is based on publicly available information and general market knowledge. It is not financial advice. The information provided is not exhaustive and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FibroBiologics, Inc. Common Stock
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2024-01-31 | Founder, Chairperson & CEO Mr. Peter O'Heeron | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.fibrobiologics.com |
Full time employees 13 | Website https://www.fibrobiologics.com | ||
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company was founded in 2021 and is based in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.